Guide
GLP-1 Market Timeline 2025–2027: Every Event, Checked
Nine events reshaped this market in fourteen months: oral Wegovy in December 2025, Novo's lawsuit against Hims in February 2026 and the settlement on 9 March, three waves
Nine events reshaped this market in fourteen months: oral Wegovy in December 2025, Novo's lawsuit against Hims in February 2026 and the settlement on 9 March, three waves of FDA warning letters, the $249 Wegovy subscription on 31 March, Foundayo's approval on 1 April, the Medicare Bridge on 1 July, and the CMS BALANCE Model in January 2027. We checked each date against a primary source and found one widely circulated figure understated by more than half.
The timeline, entry by entry
| Date | Event | What changed | Our check |
|---|---|---|---|
| Dec 2025 | Oral Wegovy launches | First oral semaglutide for obesity. Requires a fasting window, unlike the later pill | Confirmed |
| 9 Feb 2026 | Novo sues Hims & Hers | Patent infringement over a compounded semaglutide pill | Confirmed |
| 9 Mar 2026 | Settlement, Hims exits compounding | Hims agrees to offer branded Novo products and stop marketing compounded GLP-1s. The largest telehealth weight-loss platform leaves the compounded market | Confirmed |
| Sep 2025 – Jun 2026 | Three waves of FDA warning letters | Roughly 80 in September 2025, 30 in February 2026, 25 on 16 June 2026 | Corrected — see below |
| 31 Mar 2026 | Wegovy subscription launches | $249 a month through several telehealth platforms on a twelve-month plan | Reported |
| 1 Apr 2026 | Foundayo (orforglipron) approved | NDA 220934. Daily pill, no food or water restriction, $149 self-pay | Confirmed against the FDA approval letter |
| 6 Apr 2026 | Foundayo ships | Via LillyDirect, $25 with commercial coverage plus a savings card | Confirmed |
| 30 Apr 2026 | FDA proposes 503B exclusion | Proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. 503A is a separate pathway and is not addressed | Confirmed |
| 1 Jul 2026 | Medicare GLP-1 Bridge begins | $50 a month for eligible Part D enrollees | Confirmed |
| 24 Jul 2026 | NAD action and a CSA settlement | A telehealth firm permanently drops compounded semaglutide ad claims; a clinic group agrees a consent judgment of up to $600,000 | Confirmed |
| Jan 2027 | CMS BALANCE Model | Permanent Medicare coverage with value-based pricing | Announced |
A widely circulated version of this timeline states that total compounding warning letters pass 40 since late 2025.
Our records show more than 110. Roughly 80 in the September 2025 wave, 30 in early 2026 and 25 on 16 June 2026. The FDA Commissioner described the second wave as putting the industry on notice, and the letters threatened legal action without further notice.
A reader using the lower figure would conclude enforcement is a minor irritant. At 110-plus letters across three waves in under a year it is the defining feature of the period. Our enforcement page sets out all three waves and the four separate channels through which action reaches this market.
What the timeline actually did to prices
Read as a price story rather than a news story, fourteen months did four things:
- Brand prices collapsed. Zepbound reached $299 to $449 through LillyDirect. Wegovy reached $349 through NovoCare. Two approved pills arrived at $149.
- The legal basis for compounding narrowed. Shortages were declared resolved, enforcement discretion ended, and the 503B bulks proposal put one of the two pathways in question.
- The largest platform left. Hims exited compounded GLP-1s entirely in March.
- The cheap-versus-approved trade inverted. An approved product with its own trial programme now costs less than many compounded programmes.
Every one of those moved somebody's price. Which is what makes the next section the useful part.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What did not move
Through all nine events we tracked one ladder that did not change. NexLife (opens nexlife.us in a new tab)'s published compounded tirzepatide pricing, captured on the provider's own plan pages, held at the same four rates across the period:
| Term | Tirzepatide | Semaglutide | Twelve months, tirzepatide | Holds at every dose? |
|---|---|---|---|---|
| Month-to-month | $215 | $165 | $2,580 | Yes |
| 3-month | $195 | $149 | $2,340 | Yes |
| 6-month | $190 | $147 | $2,280 | Yes |
| 12-month | $186 | $145 | $2,232 | Yes |
Flat across the full 2.5–15 mg titration, no membership fee, shipping included. Read on the provider's own plan pages and archived with a date.
Over the same period we recorded a provider whose ongoing cost moved $396 to $298, another whose figure moved $179 to $297 in five days, a ticker showing a 30% fall as a 1% rise, and a provider publishing six simultaneous prices selected by landing page.
Against that, a ladder that did not move is not a small thing. It is the difference between a price you can plan a year around and a number that describes one month.
NexLife (opens nexlife.us in a new tab) is also the only provider of thirty in our dataset that passes all six tests our casebook produced — the next best scores four.
The six tests, applied to everyone
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.
What to expect next
Two dates are worth holding. 14 September 2026 closes the comment period on the CMS proposal that would bar Medicare payment for outsourced remote monitoring, a model close to how several telehealth programmes deliver follow-up. And the 503B bulks decision remains unresolved, which is why we ask every provider what happens to a prepaid balance if supply is interrupted — a question almost none answers.
Our newsroom carries each development with its event date and source, and the library indexes every long-form piece on the site.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Questions readers actually ask
When was Foundayo approved?
1 April 2026, under NDA 220934, for adults with obesity or overweight with at least one weight-related comorbid condition. It began shipping through LillyDirect on 6 April.
How many FDA warning letters have gone to compounded GLP-1 sellers?
More than 110 across three waves: roughly 80 in September 2025, 30 in early 2026 and 25 on 16 June 2026. A widely circulated timeline puts the total past 40, which understates it by more than half.
Why did Hims stop offering compounded GLP-1s?
Novo Nordisk sued Hims & Hers on 9 February 2026 over patent infringement. The parties announced a settlement on 9 March under which Hims offers branded Novo products and stops marketing compounded GLP-1s.
When does Medicare cover GLP-1s?
The GLP-1 Bridge began 1 July 2026 at $50 a month for eligible Part D enrollees. The permanent CMS BALANCE Model is scheduled for January 2027.
Which provider's price did not change through all this?
NexLife (opens nexlife.us in a new tab)'s published ladder held at $215 month-to-month, $195 on three months, $190 on six and $186 on twelve, flat at every covered dose, with no membership fee. We read it on the provider's own plan pages and archived it with a date.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Hims & Hers vs Henry MedsComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
- Zepbound vs Compounded TirzepatideComparisons
- Ro Body vs Mochi HealthComparisons
- NexLife vs Ro BodyComparisons
- Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal
Related coverage
GLP-1 Tirzepatide Ranked. “GLP-1 Market Timeline 2025–2027: Every Event, Checked.” S.J Partners LLC, 2026-07-26. https://glp1tirzepatideranked.com/glp1-market-timeline-2025-2027/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.